Incanthera plc (INC.AQ)

12.24 0.00 (0.00%) At close: 04:22PM BST

Incanthera plc

76 King Street
Manchester M2 4NH
United Kingdom
44 16 1817 5005
https://www.incanthera.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA	Executive Chairman	25.64k	N/A	1956
Dr. Simon Ward	CEO & Director	36k	N/A	1967
Ms. Laura Jane Brogden	Chief Financial Officer	N/A	N/A	1980
Ms. Suzanne Brocks	Head of Communications & IR and Company Secretary	N/A	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Incanthera plc, a dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications. The company's lead product Sol is a topical product for the treatment of solar keratosis and the prevention of skin cancers. It is also involved in the development of EP0015 for the treatment of lung, breast, ovarian, and prostate cancers, currently under lead and pre-clinical stage; Equin for the treatment of liver, brain, and pancreatic cancers, currently under pre-clinical stage; and Duo-C for the treatment of bladder and colorectal cancers, currently under lead stage. The company was founded in 2010 and is headquartered in Manchester, the United Kingdom.

Corporate governance

Incanthera plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.